Swedbank AB Has $14.02 Million Position in Insulet Co. (NASDAQ:PODD)

Swedbank AB boosted its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 152.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,688 shares of the medical instruments supplier's stock after purchasing an additional 32,456 shares during the quarter. Swedbank AB owned about 0.08% of Insulet worth $14,016,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of PODD. QRG Capital Management Inc. acquired a new position in Insulet in the 3rd quarter valued at about $297,000. Fisher Asset Management LLC increased its stake in shares of Insulet by 0.9% during the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier's stock worth $81,719,000 after purchasing an additional 3,113 shares during the period. Orion Portfolio Solutions LLC lifted its holdings in Insulet by 86.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier's stock worth $1,822,000 after purchasing an additional 3,623 shares during the last quarter. Nomura Asset Management Co. Ltd. boosted its stake in Insulet by 5.7% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier's stock valued at $35,708,000 after purchasing an additional 8,301 shares during the period. Finally, Stifel Financial Corp grew its holdings in Insulet by 2.8% in the 3rd quarter. Stifel Financial Corp now owns 10,527 shares of the medical instruments supplier's stock valued at $2,450,000 after buying an additional 290 shares in the last quarter.

Analyst Ratings Changes

PODD has been the subject of a number of recent research reports. Barclays boosted their target price on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research report on Monday, November 11th. TD Cowen increased their target price on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. JPMorgan Chase & Co. boosted their price target on Insulet from $280.00 to $330.00 and gave the company an "overweight" rating in a research note on Thursday, December 12th. BTIG Research raised their price objective on Insulet from $260.00 to $270.00 and gave the stock a "buy" rating in a research note on Friday, November 8th. Finally, Sanford C. Bernstein initiated coverage on Insulet in a research report on Wednesday, November 6th. They set an "outperform" rating and a $300.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $272.81.

Insulet Price Performance

Shares of NASDAQ PODD traded down $0.84 during midday trading on Tuesday, reaching $278.06. 130,694 shares of the company were exchanged, compared to its average volume of 527,833. Insulet Co. has a one year low of $160.19 and a one year high of $286.39. The stock has a market cap of $19.50 billion, a P/E ratio of 47.61, a PEG ratio of 3.49 and a beta of 1.23. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock's 50-day moving average price is $268.94 and its 200-day moving average price is $239.09.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.77 by $0.13. The business had revenue of $543.90 million during the quarter, compared to analysts' expectations of $518.50 million. Insulet had a return on equity of 27.98% and a net margin of 21.22%. During the same quarter in the prior year, the firm earned $0.71 EPS. On average, sell-side analysts anticipate that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, CAO Lauren Budden sold 915 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Eric Benjamin sold 12,394 shares of the company's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.